SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recruiting
Observational Study
Cancer, Metastatic
Cancer
Cancer of Pancreas
Cancer of Liver
Cancer of Stomach
Cancer Liver
Cancer of Rectum
Cancer of Kidney
Cancer of Esophagus
Cancer of Cervix
Cancer of Colon
Cancer of Larynx
Cancer, Lung
Cancer, Breast
Cancer, Advanced
Cancer Prostate
Cancer of Neck
Cancer of Skin
Neuroendocrine Tumors
Carcinoma
Mismatch Repair Deficiency
BRCA Gene Rearrangement
Non Hodgkin Lymphoma
Leukemia
Non Small Cell Lung Cancer
Cholangiocarcinoma
Glioblastoma
Central Nervous System Tumor
Melanoma
Urothelial Carcinoma
Bladder Cancer
Ovarian Cancer
Endometrial Cancer
Testicular Cancer
Breast Cancer
COVID
Myelofibrosis
Myeloproliferative Neoplasm
Myeloproliferative Disorders
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Myelodysplastic Syndromes
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50,000 (estimated)
- Sponsor
- Massive Bio, Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Pts with solid and hematological malignancies;
* Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2/Neu, Tumor mutational burden/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, AL…
Contacts